trial

Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia

NCTId NCT00073164
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 400
Sponsored by Abbott Medical Devices
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
400
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2003-07
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Divalproex Sodium Extended-Release TabletsOlanzapineRisperidone

Sponsors

Abbott Medical DevicesLead Sponsor

Investigators

1
Global Medical Information 800-633-9110Study Director

Sites

0 total

Facts & assertions

3 sourced
Enrollment
400
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
Divalproex Sodium Extended-Release Tablets
drug
Olanzapine
drug
Risperidone
drug
lead_sponsor
Abbott Medical Devices
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Global Medical Information 800-633-9110
person